Literature DB >> 35483130

The electronic prescribing of subcutaneous infusions: A before-and-after study assessing the impact upon patient safety and service efficiency.

Jonathan Hindmarsh1, Keith Holden2.   

Abstract

OBJECTIVES: To assess the impact of electronically prescribed mixed-drug infusions on the prevalence and types of prescription errors and staff time. DESIGN, SETTING AND PARTICIPANTS: Before-and-after study on acute medical wards of a large UK teaching hospital, utilising patient and staff data from the assessed wards. INTERVENTION: Electronically-generated mixed-drug infusions. MAIN OUTCOME MEASURES: (1) Rate of prescription errors (divided into errors of commission and omission); (2) time taken to process patient discharge prescriptions containing a mixed-drug infusion; and (3) time between prescription and administration of mixed-drug infusions.
RESULTS: 100 errors of omission were detected pre-intervention, whilst none were detected post intervention. 6 errors of commission were identified at baseline, whilst 2 were highlighted post intervention (p = 0.149). 14 physicochemically incompatible infusions were prescribed at baseline, post-intervention all infusions were compatible (p < 0.01). Time spent processing discharge prescriptions fell from 60 min (SME±1.7) to 26 min (SME± 2.7; p < 0.01). The median time from prescription to administration reduced from 120 min (95 % CI 106-150) to 65 min (95 % CI 43-85; p < 0.01).
CONCLUSIONS: The intervention eliminated errors of omission and facilitated the prescribing of compatible multicomponent infusions. Electronically prescribed mixed-drug infusions also reduced both the time taken to complete discharge prescriptions and the time taken to commence such infusions.
Copyright © 2022 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Electronic prescribing; Electronic prescribing and drug administration systems; Healthcare professionals; Inpatient; Subcutaneous infusion; Working practices

Mesh:

Year:  2022        PMID: 35483130     DOI: 10.1016/j.ijmedinf.2022.104777

Source DB:  PubMed          Journal:  Int J Med Inform        ISSN: 1386-5056            Impact factor:   4.730



北京卡尤迪生物科技股份有限公司 © 2022-2023.